Pfizer

AstraZeneca Leaves Door Ajar to Pfizer, Despite Hurdles

AstraZeneca's boss said on Wednesday he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's operations into the U.S. company's new three-unit model were addressed. May 15, 2014